Literature DB >> 10906723

Determination of serum protein binding affinity of inhibitors from analysis of concentration-response plots in biochemical activity assays.

R A Copeland1.   

Abstract

Serum protein binding is a common problem with synthetic molecules designed as enzyme and receptor inhibitors for in vivo clinical use. The theoretical basis of a simple method is described. In this method, the dissociation constant for serum protein binding may be determined from analysis of the shift in apparent IC(50) (concentration at which 50% inhibition of activity is observed) caused by the presence of varying concentrations of serum (or individual serum proteins) in biochemical activity assays. Knowledge of the serum protein dissociation constant and the serum concentration of the binding protein can be used to predict the amount of free compound available in vivo after dosing to achieve a specific total concentration of compound in the blood stream. Copyright 2000 Wiley-Liss, Inc.

Mesh:

Substances:

Year:  2000        PMID: 10906723     DOI: 10.1002/1520-6017(200008)89:8<1000::aid-jps4>3.0.co;2-1

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  5 in total

1.  Simulating the influence of plasma protein on measured receptor affinity in biochemical assays reveals the utility of Schild analysis for estimating compound affinity for plasma proteins.

Authors:  D Blakeley; D A Sykes; P Ensor; E Bertran; P J Aston; S J Charlton
Journal:  Br J Pharmacol       Date:  2015-10-22       Impact factor: 8.739

2.  X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases.

Authors:  Yahira M Báez-Santos; Scott J Barraza; Michael W Wilson; Michael P Agius; Anna M Mielech; Nicole M Davis; Susan C Baker; Scott D Larsen; Andrew D Mesecar
Journal:  J Med Chem       Date:  2014-03-14       Impact factor: 7.446

3.  Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovani.

Authors:  Leah S Torrie; Stephen Brand; David A Robinson; Eun Jung Ko; Laste Stojanovski; Frederick R C Simeons; Susan Wyllie; John Thomas; Lucy Ellis; Maria Osuna-Cabello; Ola Epemolu; Andrea Nühs; Jennifer Riley; Lorna MacLean; Sujatha Manthri; Kevin D Read; Ian H Gilbert; Alan H Fairlamb; Manu De Rycker
Journal:  ACS Infect Dis       Date:  2017-10-02       Impact factor: 5.084

4.  Identification of Human Alanine-Glyoxylate Aminotransferase Ligands as Pharmacological Chaperones for Variants Associated with Primary Hyperoxaluria Type 1.

Authors:  Silvia Grottelli; Giannamaria Annunziato; Gioena Pampalone; Marco Pieroni; Mirco Dindo; Francesca Ferlenghi; Gabriele Costantino; Barbara Cellini
Journal:  J Med Chem       Date:  2022-07-13       Impact factor: 8.039

5.  Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.

Authors:  Francis S Willard; Jonathan D Douros; Maria Bn Gabe; Aaron D Showalter; David B Wainscott; Todd M Suter; Megan E Capozzi; Wijnand Jc van der Velden; Cynthia Stutsman; Guemalli R Cardona; Shweta Urva; Paul J Emmerson; Jens J Holst; David A D'Alessio; Matthew P Coghlan; Mette M Rosenkilde; Jonathan E Campbell; Kyle W Sloop
Journal:  JCI Insight       Date:  2020-09-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.